Highest development stage: Phase 3

Development dropped

Gram-positive activity

Gram-negative activity

Mechanism of Action/Target pathogen: Broad spectrum antibiotic taken to phase III clinical trials but failed to be registered. It was active against Steptococcus pyogenes, S. pneumoniae, H. influenzae and many other species.

Additional information: Tsuji M, Ishii Y, Ohno A, et al. In vitro and in vivo antibacterial activities of S-1090, a new oral Cephalosporin. Antimicrobial Agents and Chemotherapy. 1995;39(11):2544.